This study focuses on Primary IgA Nephropathy (also known as Berger’s disease), which is a kidney condition where proteins called immunoglobulins build up in the kidneys and cause damage. The study will test a medication called mezagitamab (also known as TAK-079) given by subcutaneous injection under the skin, along with regular kidney disease treatments.
The purpose of this research is to determine if mezagitamab can reduce the amount of protein in the urine of people with Primary IgA Nephropathy. During the study, participants will receive either mezagitamab or placebo injections for up to 104 weeks (2 years). The medication or placebo will be given alongside their usual kidney disease treatments.
The study will monitor changes in kidney function and the amount of protein in participants’ urine throughout the treatment period. Researchers will also check for signs of improvement in other symptoms related to kidney disease, including the presence of blood in the urine. The study will track how well participants’ bodies respond to the treatment and measure the amount of medication in their blood.
Austria 
Czechia 
France 
Germany 
Hungary 
Italy 
Norway 
Poland 
Slovenia 
Spain 
Sweden 
The Netherlands 
